title: Autologous bone marrow transplantation for acute lymphoblastic leukemia.
abstract: Between December 1979 and February 1991, 89 patients with ALL received autologous BMT. Median patient age was 18.4 years. Ten patients were in first remission, 52 were in second or greater remission and 27 were in relapse at the time of transplant. Conditioning regimens utilized chemotherapy alone (5 patients) or in combination with 10-15.75 Gy total body irradiation (84 patients). Disease-free survival at 1 year is 50% for patients transplanted in first remission, 27% for those in > or = second remission and 8% for patients in relapse. Pre- and post-transplant variables were evaluated in univariate and multivariate analyses for their effect on survival and relapse. Factors significantly associated with improved survival were being transplanted in first remission and achieving a self-sustained platelet count > or = 20 x 10(9)/l in a shorter period of time. A decreased relapse rate after transplant was associated with a lower white blood count at diagnosis, being transplanted in first remission and not being transplanted in relapse.
authors.affiliation: Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
authors.forename: K
authors.initials: K
authors.lastname: Doney
authors.forename: C D
authors.initials: CD
authors.lastname: Buckner
authors.forename: L
authors.initials: L
authors.lastname: Fisher
authors.forename: F B
authors.initials: FB
authors.lastname: Petersen
authors.forename: J
authors.initials: J
authors.lastname: Sanders
authors.forename: F R
authors.initials: FR
authors.lastname: Appelbaum
authors.forename: C
authors.initials: C
authors.lastname: Anasetti
authors.forename: C
authors.initials: C
authors.lastname: Badger
authors.forename: W
authors.initials: W
authors.lastname: Bensinger
authors.forename: H J
authors.initials: HJ
authors.lastname: Deeg
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006085:Graft Survival; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012306:Risk; D016879:Salvage Therapy; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome